INSIGHTS ON SOLID DOSE MANUFACTURING

• Powder Rheology: Gateway For Tablet Sticking Insights

  Powder rheology offers a scientific method to predict and mitigate tablet sticking issues, helping to ensure smoother pharmaceutical production cycles through early material and tooling selection.

• The Crucial Role Of Cleaning In Effective VPHP Decontamination For Isolators

  Effective isolator cleaning is crucial for vapor phase hydrogen peroxide (VPHP) decontamination. Proper tools, techniques, and training ensure sterility, and regulatory compliance.

• Die Bore Cracking: How To Achieve Reliable Tablet Production

  Die bore cracking is a significant issue in tablet manufacturing, affecting the quality of the tablets and potentially damaging the tablet press. Explore how to analyze for and prevent this damage.

• The Critical Role Of Weight Uniformity In Tablet Manufacturing

  For tablet manufacturers, tablet weight uniformity plays an essential role in ensuring pharmaceutical products deliver accurate amounts of key ingredients in a formulation.

• Navigating High-Potency OSD Manufacturing

  4/13/2026

  Learn how containment strategy, process design, and early risk‑based decisions influence operator protection, compliance, and long‑term manufacturing success as potency levels continue to rise.

• Spray Dry Biologics For Oral Dosage Forms

  5/15/2026

  Spray drying enables stable oral delivery of biologics by creating protective dry powders, improving bioavailability, stability, and targeted release compared with traditional formulation methods.

• 6 Strategic Pillars For Selecting A Drug Packaging Partner

  4/14/2026

  Early engagement with an expert packaging partner supports safe, cost-effective drug development and logistical success from precommercial stages through full market launch.

• The Future Of Oral Solid Dose Development And Innovation

  2/27/2025

  Tom Sellig, CEO of Adare, discusses the ongoing relevance of small molecules, oral solid dose development, trends like GLP-1, and innovations like 3D printing in pharmaceuticals.

• Closing The Duration Gap In FDA-Approved Long-Acting Contraceptives

  7/17/2024

  A gap exists between three months and three years in FDA-approved long-acting contraceptives (LACs). A microsphere formulation enables sustained release over a six to twelve-month period.